Tuesday, May 21, 2013 Last update: 6:35 PM
Company Tech News as it Breaks

Regulus Therapeutics Inc.

print this company - email to a friend - join our eNewsletter
News articles for Regulus Therapeutics Inc.:

Tuesday, May 21, 2013

  • Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference
    LA JOLLA, Calif., May 21, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Garry E. Menzel, Ph.D., Chief Operating Officer and Executive Vice President, Finance, will present a company overview at ... read more

Tuesday, May 14, 2013

Tuesday, May 7, 2013

Wednesday, April 24, 2013

  • Regulus to Present at 12th Annual Needham Healthcare Conference
    LA JOLLA, Calif., April 24, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer, will present a company overview at the 12(th) Annual Needham ... read more

Monday, April 1, 2013

  • Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors
    LA JOLLA, Calif., April 1, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has appointed William H. Rastetter, Ph.D. to its Board of Directors effective immediately. "We are ... read more

Thursday, March 28, 2013

  • Regulus to Present at Future Leaders in the Biotech Industry Conference
    LA JOLLA, Calif., March 28, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Garry E. Menzel, Ph.D., Chief Operating Officer and Executive Vice President, Finance, will present a company overview at the ... read more

Tuesday, February 26, 2013

  • Regulus to Present at Cowen and Company 33rd Annual Healthcare Conference
    LA JOLLA, Calif., Feb. 26, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Garry E. Menzel, Ph.D., Chief Operating Officer and Executive Vice President, Finance, will present a company overview at the ... read more

Wednesday, February 20, 2013

  • Regulus Reports Fourth Quarter and Year-End 2012 Financial Results and Highlights
    LA JOLLA, Calif., Feb. 20, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported its financial results for the fourth quarter and year-ended December 31, 2012 and recent company highlights. "In 2012, we successfully achieved significant strategic and ... read more

Wednesday, February 13, 2013

Monday, February 4, 2013

  • Regulus to Present at Two Upcoming Investor Conferences
    LA JOLLA, Calif., Feb. 4, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus, will present a company overview at the 15(th) Annual BIO ... read more

Thursday, January 31, 2013

  • Regulus Appoints Mark G. Foletta to its Board of Directors
    LA JOLLA, Calif., Jan. 31, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the appointment of Mark G. Foletta to its Board of Directors and Audit Committee, effective immediately. "We are ... read more

Thursday, January 3, 2013

  • Regulus to Present at 31st Annual J.P. Morgan Healthcare Conference
    LA JOLLA, Calif., Jan. 3, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus, will present a company overview at the 31(st) Annual J.P. ... read more

Thursday, December 20, 2012

  • Regulus Announces Addition to Russell 2000 Index
    LA JOLLA, Calif., Dec. 20, 2012 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it was included on the preliminary list of IPO additions to the Russell 2000® Index to be effective at ... read more

Monday, December 3, 2012

  • Regulus to Host NASDAQ Closing Bell Ceremony on December 5, 2012
    LA JOLLA, Calif., Dec. 3, 2012 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it will host The NASDAQ Stock Market Closing Bell at the NASDAQ MarketSite in Times Square, New York on ... read more

Tuesday, November 27, 2012